I02-Macromolecular Crystallography
I03-Macromolecular Crystallography
I24-Microfocus Macromolecular Crystallography
VMXm-Versatile Macromolecular Crystallography microfocus
|
Abstract: Crystallization is a key step in drug purification, offering low cost and facile scalability. The thesis investigates the role of heterogeneous nucleation templates in enhancing crystallization efficiency and controllability with a focus on biopharmaceutical applications, and examines the mechanisms of template-mediated nucleation, crystal growth, and morphology control using carbon-based templates, polymeric hydrogel templates, and microbial bio-templates. The interaction between inorganic salt and proteins was investigated and proteins themselves were also applied as the macromolecular templates. Carbon-based materials, including graphite and graphene oxide (GO), were investigated for their influence on lysozyme crystallization. Graphite reduced nucleation time by 57% compared to those without templates and demonstrated edge adsorption. GO exhibited a nonlinear effect, accelerating nucleation at low lysozyme concentrations (30 mg mL-1) while inhibiting it at higher concentrations (over 50 mg mL-1). Furthermore, a second strategy was pursued using heterogeneous templates based on poly (ethylene glycol) diacrylate (PEGDA) hydrogel microspheres (HMS). In contrast to the adsorption mechanism, the PEGDA HMS acts by releasing precipitant (0- 4 M NaCl) to create localized supersaturation gradients, thereby reducing nucleation time by 79%. Based on the mechanisms of templated crystallization observed in the lysozyme system, this work sought to explore the universality of these effects in inorganic systems critical to biomineralization and disease. The interaction between proteins and inorganic salts was further investigated in two model systems: lithium carbonate (Li'CO') and calcium oxalate (CaOx) with proteins (lysozyme, bovine haemoglobin and mRFP). In both systems, inorganic salt crystals serve as templates that influence subsequent protein adsorption and crystallization, leading to the formation of protein-salt composite crystal structures. Elevated salt concentrations consistently promoted nucleation kinetics. Proteins, however, exhibited complex effects: At low supersaturation, proteins like lysozyme inhibited Li'CO' nucleation by chelating Li'. Conversely, at high supersaturation, proteins self-assemble into oligomers or aggregates, providing additional nucleation sites and accelerating nucleation. In the CaOx system, lysozyme enhanced nucleation across its tested concentration range (0-70 mg mL-1). To bridge our findings on artificial templates to biological contexts, in vivo crystallization is further explored. Inspired by nature, the production of intracellular crystals in Bacillus thuringiensis (Bt) was studied, and its Cry1Ac gene was applied to form a crystal scaffold (CS) as the bio-template to generate crystal nanoparticles in Escherichia coli (E. coli). Through adaptive laboratory evolution (ALE) via serial passaging, we achieved a nearly tenfold increase in protein fluorescence level and produced biologically active nanocrystals with high solubility under alkaline conditions. By integrating heterogeneous nucleation theory with biomimetic strategies, our work elucidates diverse templating mechanisms, including surface, the creation of local supersaturation gradients, and inorganic salt templates. These understandings enable the rational design of templates to control crystallization outcomes. Furthermore, we establish a platform that applying the Cry gene from Bt as the crystal scaffold to function as bio-templates inside cells, demonstrating their potential in high-yield production of bioactive nanocrystals.
|
Apr 2026
|
|
I02-Macromolecular Crystallography
|
Diamond Proposal Number(s):
[31430, 36304]
Abstract: Purpose: To characterize structural and biomechanical changes following ex vivo treatment of rabbit sclera with the bacteriochlorophyll derivative WST11 and near-infrared (NIR) light.
Methods: Enucleated left scleras of 10 rabbits were cross-linked by a 20-min topical application of WST11 solution, followed by 30-min NIR irradiation (10 mW/cm2). Paired right eyes served as untreated controls. Scleral tangent modulus and ultimate tensile strength were obtained from tensile strip testing. Collagen molecular-level nanostructure was measured using wide-angle X-ray scattering (WAXS). Scleral fibrillar-level microstructure was assessed using second harmonic generation (SHG) and two-photon fluorescence (TPF) imaging.
Results: WST11/NIR treatment increased scleral tangent modulus by an average of 79% for strains between 1.5% and 3% (p < 0.05), while ultimate tensile strength increased by 140% (control: 1.719 MPa, treated: 4.134 MPa, p < 0.01). WAXS indicated that collagen molecular spacing (control: 1.485 nm/treated: 1.480 nm, p = 0.65), spatial disorder (47.6 a.u./47.6 a.u., p > 0.99), and anisotropy (0.935 a.u./1.157 a.u., p = 0.09) were not significantly affected by treatment. No marked treatment effects on collagen fibril bundle organization were observable by SHG imaging. TPF imaging revealed additional crimped fibrous structures in the outer half of the tissue depth in treated specimens, indicative of enhanced collagen cross-linking.
Conclusions: WST11/NIR treatment significantly increased the stiffness of the ex vivo rabbit sclera. The origin of the stiffening effect is consistent with the formation of collagen cross-links that are predominantly extrafibrillar in nature. Further research is needed to establish the full mechanism, efficacy, and safety of the method as a potential myopia treatment.
|
Mar 2026
|
|
I02-Macromolecular Crystallography
I03-Macromolecular Crystallography
I24-Microfocus Macromolecular Crystallography
|
Diamond Proposal Number(s):
[38316]
Open Access
Abstract: The DUF4465 family (DUF, domain of unknown function) contains more than 1000 members distributed across eight bacterial clades with species from diverse microenvironments including various gut microbiomes, hydrothermal vents, and soil. In the gut commensal Bacteroides thetaiotaomicron (B. theta), DUF4465 containing proteins act as high-affinity B12–binding proteins that scavenge this cofactor to ensure bacterial survival. Such B12 capture is essential for bacteria that have lost the ability to synthesize B12 de novo. This raises the question of whether B12-binding is ubiquitous across this family of proteins. Here, we show that B12-binding is a recurrent function of eight distantly related members of the DUF4465 family. It is reasonable to conclude that B12-binding is a common function of most DUF4465 proteins. These results establish DUF4465 as a structurally conserved family of augmented β-jellyroll B12-binding proteins with widespread roles in microbial competition for this essential cofactor.
|
Mar 2026
|
|
I02-Macromolecular Crystallography
|
Martin
Orecchia
,
Katherine
Welbeck
,
Jason
Dexter
,
Laura
Hook
,
Chika
Akinseye
,
Marcin
Kot
,
Alan
Lewis
,
Don
Somers
,
Tejinder
Bhinder
,
Paul
Hamblin
,
Sarah
Elsey
,
David
Willé
,
Steven
Grant
Open Access
Abstract: This study describes the affinity maturation, molecular engineering, and preclinical assessment of depemokimab, an enhanced anti-interleukin-5 antagonist antibody. The molecular design objective for depemokimab was to generate a therapeutic antibody enabling a less frequent dosing regimen of once every 6 months compared with every 4 weeks for mepolizumab. Mepolizumab is a marketed monoclonal antibody used as an add-on prescription maintenance treatment for patients with severe asthma with an eosinophilic phenotype and other eosinophilic-associated disorders. A complementarity-determining region restricted affinity maturation strategy was used where affinity improved interleukin-5 binding antibody variants were subject to affinity driven selective pressure and identified using the Adimab yeast-based platform. Improved complementarity-determining region variants were combined with serum half-life extending amino acid mutations introduced into the fragment crystallizable region of the antibody. When compared with mepolizumab, depemokimab demonstrated improved in vitro interleukin-5 neutralization in a TF-1 (human erythroleukemia) functional cell assay. In vivo, depemokimab displayed significantly extended pharmacokinetic performance and pharmacodynamic duration determined via eosinophil suppression in cynomolgus monkey (Macaca fascicularis). These data provide compelling evidence that a less frequent dosing regimen for depemokimab in humans is possible and supported the advancement of depemokimab into a Phase I study in patients with asthma.
|
Dec 2025
|
|
I02-Macromolecular Crystallography
|
Diamond Proposal Number(s):
[9948]
Abstract: Copper is an essential micronutrient for bacteria, needed for important copper enzymes such as terminal respiratory oxidases. However, in excess, copper is toxic to bacteria. This toxicity is caused by its ability to bind tightly to proteins through the formation of Cu-Cys and Cu-His bonds. To control toxicity, bacteria have evolved homeostatic systems to safely handle the copper they need while efficiently sequestering and effluxing excess copper ions. We previously found that GapA, the abundant glycolytic glyceraldehyde-3-phosphate dehydrogenase enzyme in the Staphylococcus aureus cytosol, becomes associated with copper within cells cultured in medium containing excess copper. We found that this association of GapA with copper resulted in inhibition of its enzyme activity. Here, we have characterised this binding of copper ions to S. aureus GapA in vitro to determine the mechanism of copper inhibition of GAPDH. We found that purified recombinant GapA binds a single Cu(I) ion with high affinity. Crystallographic structural determination showed association of this copper ion with two active site residues, Cys151 and His178, known to be important for catalysis. This observation was confirmed by characterisation of mutated variants lacking these residues, which showed reduced ability to bind Cu(I) ions. Finally, we demonstrated that the cytosolic copper metallochaperone, CopZ, exhibits a tighter affinity for Cu(I) and can remove copper from GapA in vitro. Together, our data demonstrate the mechanism by which excess copper binds to the S. aureus GapA enzyme and irreversibly inhibit its activity and how the cellular homeostasis system is capable of resolving this inhibition.
|
Dec 2025
|
|
I02-Macromolecular Crystallography
|
Elisabetta
Armani
,
Andrea
Rizzi
,
Daniela
Miglietta
,
Irene
Bassanetti
,
Francesco
Amadei
,
Giandomenico
Brogin
,
Carmelida
Capaldi
,
Fabio
Rancati
,
Chiara
Carnini
,
Sergio
Xanxo Fernandez
,
Maurizio
Civelli
,
Paola
Puccini
,
Marta
Bellini
,
Andrew
Jennings
,
Robert A.
Heald
,
Lilian
Alcaraz
,
Jonathan M.
Sutton
,
Harry
Finch
,
Mary
Fitzgerald
,
Craig
Fox
,
Gino
Villetti
Abstract: The inhibitors of neutrophil elastase (NE) have long attracted interest for the treatment of respiratory diseases. We report the breakthrough of a new potent, selective NE inhibitor with a 24 h duration of action: CHF-6333, is currently undergoing clinical studies for the inhaled treatment of bronchiectasis (BE). The story of the discovery project to identify novel small molecules that inhibit extracellular elastase in the lung with prolonged activity is described. Medicinal chemistry investigation, supported by docking studies, led to N-quaternary compounds with an in vitro profile suitable for inhalatory administration. Compound 15 emerged from in vivo pharmacokinetic and pharmacodynamic studies, also showing safety and no off-target effects in vitro. Salt screening of different counterions, in conjunction with in vivo local irritancy testing, aided in the selection of compound 15-xinafoate (CHF-6333). Efficacy in a lung injury model and no findings in non-GLP toxicity studies promoted CHF-6333 as a clinical candidate.
|
Nov 2025
|
|
I02-Macromolecular Crystallography
|
Open Access
Abstract: The trematode liver fluke Fasciola hepatica causes the neglected tropical disease fascioliasis in humans and is associated with significant losses in agricultural industry due to reduced animal productivity. Triosephosphate isomerase (TPI) is a glycolytic enzyme that has been researched as a drug target for various parasites, including F. hepatica. The high-resolution crystal structure of F. hepatica TPI (FhTPI) has been solved at 1.51 Å resolution in its monoclinic form. The structure has been used to perform molecular-docking studies with the most successful fasciolocide triclabendazole (TCBZ), which has recently been suggested to target FhTPI. Two FhTPI residues, Lys50 and Asp51, are located at the dimer interface and are found in close proximity to the docked TCBZ. These residues are not conserved in mammalian hosts.
|
Sep 2025
|
|
I02-Macromolecular Crystallography
|
Xuqing
Zhang
,
Harshil
Dhruv
,
Qiaolin
Deng
,
Matthew
Tudor
,
Nelisa
Bechtel
,
Rakesh
Nagilla
,
Larry
Jolivette
,
Cory T.
Rice
,
Peter
Orth
,
Elham
Behshad
,
Corey
Strickland
,
Helai P.
Mohammad
,
Longchuan
Bai
,
Donna
Mceachern
,
Shaomeng
Wang
,
Zhihua
Sui
,
E. Scott
Priestley
Abstract: Immunosuppressive Tregs, regulated by IKZF2 (Helios), promote tumor immune evasion and resistance to immune checkpoint therapies (ICTs). Targeting IKZF2 degradation offers a promising cancer immunotherapy approach. We developed a novel series of iso-indolinone-based glutarimides, identifying compound 55 as a potent, selective IKZF2 degrader with >90% Dmax in Jurkat cells, outperforming benchmarks DKY709 and PVTX-405. It exhibits strong selectivity over IMiD neo-substrates, favorable solubility, metabolic stability, and oral bioavailability in rodents. PK/PD studies confirmed profound, persistent IKZF2 degradation in mouse spleen and thymus after a single oral dose. As a promising early-stage tool, 55 provides a foundation for further preclinical evaluation in cancer immunotherapy.
|
Aug 2025
|
|
I02-Macromolecular Crystallography
I03-Macromolecular Crystallography
I04-Macromolecular Crystallography
I23-Long wavelength MX
|
Jessica
Domenech
,
Nuttawan
Pramanpol
,
Claudine
Bisson
,
Sveta E.
Sedelnikova
,
Joshua R.
Barrett
,
Abdul A. A. B.
Dakhil
,
Vitaliy
Mykhaylyk
,
Ali S.
Abdelhameed
,
Stephen E.
Harding
,
David W.
Rice
,
Patrick J.
Baker
,
Juan
Ferrer
Diamond Proposal Number(s):
[300, 1218, 24447, 31850]
Open Access
Abstract: Enzymes from salt-in halophiles are stable in conditions of low water activity with applications in chiral synthesis requiring organic solvents, yet the origins of such stability remains poorly understood. Here we describe the molecular basis of the reaction mechanism and dual NADH/NADPH-specificity of D2HDH, a 2-hydroxyacid dehydrogenase from the extreme halophile Haloferax mediterranei, an organism whose proteins have to remain active in high intracellular concentrations of KCl. Halophilic adaptations of D2HDH include the expected acidic surface and a reduction in hydrophobic surface resulting from a lower lysine content. Structure determination of crystals of D2HDH grown with KCl showed that bound K+ ions were coordinated predominantly by clusters of main chain protein carbonyl ligands, with no involvement of the numerous exposed surface carboxyls. Structural comparisons identified similar sites in other halophilic proteins suggesting that the generic use of carbonyl clusters to coordinate K+ ions may also contribute in a carboxylate-independent way to the stabilisation of the folded state of the protein in its high salt environment.
|
Aug 2025
|
|
I02-Macromolecular Crystallography
I04-Macromolecular Crystallography
I24-Microfocus Macromolecular Crystallography
|
Madeline E.
Kavanagh
,
Kirsty J.
Mclean
,
Sophie H.
Gilbert
,
Cecilia N.
Amadi
,
Matthew
Snee
,
Richard B.
Tunnicliffe
,
Kriti
Arora
,
Helena I. M.
Boshoff
,
Alexander
Fanourakis
,
Maria Jose
Rebollo-Lopez
,
Fatima
Ortega
,
Colin W.
Levy
,
Andrew W.
Munro
,
David
Leys
,
Chris
Abell
,
Anthony G.
Coyne
Diamond Proposal Number(s):
[8997, 17773, 24447]
Open Access
Abstract: Tuberculosis is the deadliest infectious disease in history and new drugs are urgently required to combat multidrug-resistant (MDR) strains of Mycobacterium tuberculosis (Mtb). Here, we exploit the relience of Mtb on host-derived cholesterol to develop a novel class of antitubercular compounds that target Mtb CYP125 and CYP142; the enzymes that catalyze the first step of cholesterol metabolism. A combination of fragment screening and structure-based drug design was used to identify a hit compound and guide synthetic optimization of a dual CYP125/142 ligand 5m (KD 40–160 nM), which potently inhibits enzyme activity in vitro (KI < 100 nM), and the growth of Mtb in extracellular (MIC99 0.4–1.5 μM) and intracellular assays (IC50 1.7 μM). The structural data and lead compounds reported here will help study Mtb cholesterol metabolism and guide the development of novel antibiotics to combat MDR Mtb.
|
Jul 2025
|
|